Abbott Reports 2 Years Data from the LIFE-BTK Study of Esprit BTK System to Treat Peripheral Artery Disease Below the Knee
Shots:
- The LIFE-BTK clinical evaluation of Esprit BTK Everolimus Eluting Resorbable Scaffold System vs balloon angioplasty in patients (n= >260) with peripheral artery disease (PAD) below the knee (BTK)
- Study depicted the system’s sustained efficacy & ability to open vessels & reducing reclosures, 90.3% avoided reintervention at 24mos. & 61.5% vs 32.8% had higher freedom from chronic limb-threatening ischemia after 2yrs.; improvement of 35.2% in reducing vessel re-narrowing was observed at 1yr. Data was highlighted at VIVA 2024
- Abbott has also initiated a Post-Approval Study (PAS) to determine the system’s continued safety & efficacy for treating chronic limb-threatening ischemia (CLTI) in real-world patients with blocked arteries below the knee
Ref: Abbott | Image: Abbott
Related News: Abbott Reports the Initiation of TRANSCEND Trial Assessing Deep Brain Stimulation System to Manage Severe Depression (TRD)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
